Trade Hikma Pharmaceuticals PLC - HIK CFD

Trading Conditions
Spread0.06
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
£1,000.00
Overnight funding adjustment
Charges from full value of position
-0.025295 %
(-£4.81)

Trade size with leverage ~ £20,000.00

Short position overnight funding adjustment ~ £19,000.00


-0.025295%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
£1,000.00
Overnight funding adjustment
Charges from full value of position
0.003377 %
(£0.64)

Trade size with leverage ~ £20,000.00

Short position overnight funding adjustment ~ £19,000.00


0.003377%
Overnight funding adjustment time21:00 (UTC)
CurrencyGBP
Min traded quantity1
Margin5%
Stock exchangeUnited Kingdom of Great Britain and Northern Ireland
Commission on trade0%
Key Stats
Prev. Close18.52
Open18.38
1-Year Change-1.76%
Day's Range18.23 - 18.66

Hikma Company profile

Discover the latest Hikma share price today with our comprehensive live chart.

Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017. 

According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.

Latest shares articles

Lloyds share price forecast: An attractive dividend stock?
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
13:36, 8 July 2024
Exterior of Infosys headquarters
Infosys shareholders: Who owns the most INFY stock?
Who are the major shareholders and decision-makers of Infosys?
07:12, 29 April 2024
Tesla logo atop of a Tesla Dealership illuminated at night.
Tesla shareholders: Who owns the most TSLA stock?
In this guide to Tesla’s ownership structure, we look at the biggest TSLA shareholders – both institutional and individual
08:00, 19 April 2024
US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.

the simplicity and the pros of this app makes it amazing and a useful app

Hafsa

I have already tested many brokers and I can definitely say that Capital.com is the most professional trading tool.

PaCeKw

Capital.com is a good broker. I haven't had any problems with the trading platform but i qould advise that they add an option for either using lots or units.

Mr-phenom

I am in the first time but I look this website in YouTube there's a very good and safe platform for a traders Thinks for taking my opinion

MUHAMMAD JALIL MUHAMMAD ASGHAR

great UI, simple platform, low spreads, great coverage

Jihad Kattar

The videos are easy to follow, i get my profits and downs and understand the market now even more. This app is very well to understand. I would recommend this app to friends if they want to know.

Customer

Good and amazing app for trading and easy setups easy and smooth buy and sell amazing

QAISAR ALI

Excellent for people who would like to get and build all the experience needed to navigate to Stock Market.

Johnsy81

Overall my experience is very good with capital, the one best thing is they give you call support with most other broker apps don’t gives.

Ranjit

I have been usingCapital.comm platform for a year now. I did have some issues with using the platform in the earlier days but I received excellent support from Capital.com guiding me in the process of learning about the platform and put me on track. I am very happy with this platform and find it very easy to use for my trading needs. Capital.com also arranged a series of trading webinars last summer, which I attended and benefited from.

Dr Anjum Pervez

The best app for trade ever I tried to much trade app and this is the best

Moamen

Great website, easy to use and user friendly. Lot of markets to trade with. Good database of information and learning tutorials for beginner. Great customer support. I had some issues and they helped me solve them rapidly. One of the best broker, I recommend.

Nicolas Crampet

Trusted trading Platform Capital.com is the most trusted trading platform I ever experienced. Even without taking any demo,I have started funding and it’s going well. It is a very easy platform for the beginners and can have better trading experience by using this

JEYAKUMAR

great app, love the weekly and monthly insights, and review they send about my trading habits. spread for gold is usually 0.3 but at times fluctuates up to 0.9 this often makes it hard trading on the low time frames and not losing my position to spread even if my bias was correct, if the spread was better I'd give 5 star.

chris hoeben

Capital.com is the best broker of all time and I Should give it five stars but there is a small issue about execution of my orders through traddingview it is a bit slow. But the execution of orders directly from the capital.com App or Website is absolutely fast and apart from that everything is simple incredible.

IKOFO MOISE

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading